PL2825037T3 - Gryzonie eksprymujące sekwencje immunoglobuliny wrażliwej na pH - Google Patents

Gryzonie eksprymujące sekwencje immunoglobuliny wrażliwej na pH

Info

Publication number
PL2825037T3
PL2825037T3 PL13714127T PL13714127T PL2825037T3 PL 2825037 T3 PL2825037 T3 PL 2825037T3 PL 13714127 T PL13714127 T PL 13714127T PL 13714127 T PL13714127 T PL 13714127T PL 2825037 T3 PL2825037 T3 PL 2825037T3
Authority
PL
Poland
Prior art keywords
immunoglobulin sequences
sensitive
rodents expressing
rodents
expressing
Prior art date
Application number
PL13714127T
Other languages
English (en)
Other versions
PL2825037T4 (pl
Inventor
John Mcwhirter
Lynn Macdonald
Joel H Martin
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PL2825037T3 publication Critical patent/PL2825037T3/pl
Publication of PL2825037T4 publication Critical patent/PL2825037T4/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Knock-in vertebrates, e.g. humanised vertebrates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/15Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/01Animal expressing industrially exogenous proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/20Pseudochromosomes, minichrosomosomes
    • C12N2800/204Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL13714127T 2012-03-16 2013-03-15 Gryzonie eksprymujące sekwencje immunoglobuliny wrażliwej na pH PL2825037T4 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261612126P 2012-03-16 2012-03-16
US201261611950P 2012-03-16 2012-03-16
US201261613352P 2012-03-20 2012-03-20
US201261736930P 2012-12-13 2012-12-13
PCT/US2013/032036 WO2013138712A1 (en) 2012-03-16 2013-03-15 Non-human animals expressing ph-sensitive immunoglobulin sequences
EP13714127.1A EP2825037B1 (en) 2012-03-16 2013-03-15 Rodents expressing ph-sensitive immunoglobulin sequences

Publications (2)

Publication Number Publication Date
PL2825037T3 true PL2825037T3 (pl) 2019-10-31
PL2825037T4 PL2825037T4 (pl) 2020-03-31

Family

ID=48045752

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13714127T PL2825037T4 (pl) 2012-03-16 2013-03-15 Gryzonie eksprymujące sekwencje immunoglobuliny wrażliwej na pH

Country Status (24)

Country Link
US (4) US9801362B2 (pl)
EP (2) EP2825037B1 (pl)
JP (4) JP6228589B2 (pl)
KR (3) KR102213535B1 (pl)
CN (2) CN107361011B (pl)
BR (1) BR112014022855A2 (pl)
CA (1) CA2865645A1 (pl)
CY (1) CY1121864T1 (pl)
DK (1) DK2825037T3 (pl)
ES (1) ES2737990T3 (pl)
HK (1) HK1200270A1 (pl)
HR (1) HRP20191333T1 (pl)
HU (1) HUE045537T2 (pl)
IL (4) IL234237B (pl)
LT (1) LT2825037T (pl)
MX (2) MX355944B (pl)
NZ (3) NZ629077A (pl)
PL (1) PL2825037T4 (pl)
PT (1) PT2825037T (pl)
RS (1) RS59076B1 (pl)
RU (2) RU2664473C2 (pl)
SG (3) SG11201405171WA (pl)
SI (1) SI2825037T1 (pl)
WO (1) WO2013138712A1 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
MX358220B (es) 2011-11-30 2018-08-10 Chugai Pharmaceutical Co Ltd Portador que contiene fármaco en la célula para formar el inmunocomplejo.
PT2825037T (pt) 2012-03-16 2019-08-07 Regeneron Pharma Animais não humanos que expressam sequências de imunoglobulinas sensíveis ao ph
SG10201607727PA (en) * 2012-03-16 2016-11-29 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
HUE053310T2 (hu) 2012-03-16 2021-06-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ugyanennek az elõállítására
JP6309521B2 (ja) 2012-08-13 2018-04-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. pH依存性結合特性を有する抗PCSK9抗体
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
LT2840892T (lt) * 2013-02-20 2018-07-25 Regeneron Pharmaceuticals, Inc. Nežmogaus tipo gyvūnai su modifikuotomis imunoglobulino sunkiųjų grandinių sekomis
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US9738702B2 (en) * 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
MY183415A (en) 2014-12-19 2021-02-18 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016117346A1 (en) * 2015-01-22 2016-07-28 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
CN107438622A (zh) * 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
AU2016258115A1 (en) 2015-05-06 2017-11-23 Janssen Biotech, Inc. Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CA3011359A1 (en) * 2016-01-13 2017-07-20 Regeneron Pharmaceuticals, Inc. Rodents having an engineered heavy chain diversity region
AU2017268458B2 (en) 2016-05-20 2022-07-21 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide RNAS
CA3026088A1 (en) 2016-06-03 2017-12-07 Regeneron Pharmaceuticals, Inc. Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
CN111556895B (zh) 2017-11-14 2024-09-13 中外制药株式会社 抗-c1s抗体及使用方法
WO2019190922A1 (en) 2018-03-24 2019-10-03 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
KR20200135435A (ko) 2018-03-26 2020-12-02 리제너론 파아마슈티컬스, 인크. 항-PfRH5 항체 및 이의 항원 결합 단편
JP7328243B2 (ja) 2018-03-26 2023-08-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療薬を試験するためのヒト化げっ歯類
CN108486126A (zh) * 2018-03-27 2018-09-04 重庆金迈博生物科技有限公司 一种核酸分子及其在人源化抗体中的应用
JP7523358B2 (ja) 2018-06-13 2024-07-26 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ ムスカリン受容体m3に対して阻害活性を有するペプチド
IL305557A (en) 2018-06-14 2023-10-01 Regeneron Pharma Non-human animals with transgenic DH–DH rearrangement capacity, and their uses
EP4211155A1 (en) 2020-09-11 2023-07-19 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
IL303626A (en) 2020-12-16 2023-08-01 Regeneron Pharma Mice expressing human FC alpha receptors
US20240317849A1 (en) 2020-12-23 2024-09-26 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
WO2024056044A1 (en) * 2022-09-16 2024-03-21 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals and methods for producing heavy-chain antibodies

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
WO1991012023A2 (en) 1990-02-16 1991-08-22 Boston Biomedical Research Institute Hybrid reagents capable of selectively releasing molecules into cells
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US7067284B1 (en) 1992-01-27 2006-06-27 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5999908A (en) 1992-08-06 1999-12-07 Abelow; Daniel H. Customer-based product design module
AU2466895A (en) * 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69636868T2 (de) 1995-08-29 2007-10-25 Kirin Beer Kabushiki Kaisha Chimäres tier und methode zu dessen herstellung
JP2007312792A (ja) * 1995-08-29 2007-12-06 Kirin Pharma Co Ltd キメラ動物およびその作製法
WO1998046645A2 (en) 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
DE69838454T2 (de) 1997-10-03 2008-02-07 Chugai Seiyaku K.K. Natürlicher menschlicher antikörper
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
CA2421760A1 (en) 2000-09-08 2002-03-14 Massachusetts Institute Of Technology G-csf analog compositions and methods
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2003031656A1 (en) 2001-10-05 2003-04-17 United States Environmental Protection Agency Genetic testing for male factor infertility
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
EP3269235B1 (en) 2001-11-30 2022-01-26 Amgen Fremont Inc. Transgenic mice bearing human ig lambda light chain genes
DK1512015T3 (da) 2002-06-12 2009-07-06 Genencor Int Fremgangsmåder til forbedring af bindingsegenskaber hos et molekyle
CA2488836A1 (en) 2002-06-12 2003-12-24 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
CA2965865C (en) 2002-07-18 2021-10-19 Merus N.V. Recombinant production of mixtures of antibodies
EP1439234A1 (en) 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
WO2004065611A1 (ja) 2003-01-21 2004-08-05 Chugai Seiyaku Kabushiki Kaisha 抗体の軽鎖スクリーニング方法
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395016A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
MXPA06000562A (es) 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
CN1560081A (zh) 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链-κ轻链小鼠作为制备人源化单克隆抗体和应用
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
KR20070084069A (ko) * 2004-10-08 2007-08-24 도만티스 리미티드 Tnfr1에 대한 단일 도메인 항체 및 이의 사용 방법
ES2463476T3 (es) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Método para generar un ratón homocigótico para una modificación genética
WO2007001422A2 (en) 2004-10-22 2007-01-04 Medimmune, Inc. High affinity antibodies against hmgb1 and methods of use thereof
RU2290442C2 (ru) * 2005-03-21 2006-12-27 Всероссийский государственный научно-исследовательский институт животноводства (ВИЖ) Способ трансформации стволовых клеток семенников животных in vivo
PT1861116E (pt) * 2005-03-25 2015-11-04 Regeneron Pharma Formulações de antagonista do vegf
JP2008538912A (ja) 2005-04-29 2008-11-13 イナート・ファルマ 遺伝子導入動物および組換え抗体の製造方法
WO2007065433A2 (en) 2005-12-05 2007-06-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
EP2505058A1 (en) 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
DK2769992T3 (da) 2006-10-02 2021-03-22 Regeneron Pharma Humane antistoffer med høj affinitet for human IL-4-receptor
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
EP2086998B1 (en) * 2006-10-11 2011-12-07 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2008112922A2 (en) 2007-03-13 2008-09-18 National Jewish Medical And Research Center Methods for generation of antibodies
ITMI20071522A1 (it) 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
BRPI0816785A2 (pt) 2007-09-14 2017-05-02 Adimab Inc bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
AU2008316661B2 (en) * 2007-10-26 2013-05-23 Oklahoma Medical Research Foundation Monoclonal antibodies against activated and unactivated protein C
JP5591712B2 (ja) 2007-12-14 2014-09-17 ノボ・ノルデイスク・エー/エス ヒトnkg2dに対する抗体とその使用
US8236527B2 (en) * 2008-03-14 2012-08-07 Humanzyme Limited Recombinant production of authentic human proteins using human cell expression systems
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
ES2906344T3 (es) * 2008-06-27 2022-04-18 Merus Nv Animal murino transgénico productor de anticuerpos
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9拮抗劑類
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
LT2346994T (lt) * 2008-09-30 2022-03-10 Ablexis, Llc Knock-in pelė, skirta chimerinių antikūnų gamybai
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
RU2011129459A (ru) 2008-12-18 2013-01-27 Эрасмус Юниверсити Медикал Сентр Роттердам Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение
CN102427978B (zh) 2009-05-07 2016-01-20 沃尔沃建筑设备公司 工程机械和用于操作工程机械的方法
JP5804521B2 (ja) 2009-05-29 2015-11-04 モルフォシス・アー・ゲー コレクション及びその使用方法
EP3916011A1 (en) 2009-06-26 2021-12-01 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
AU2010271586B2 (en) 2009-07-16 2016-08-11 Wageningen Universiteit Regulation of zinc deficiency and tolerance in plants
GB2472108B (en) * 2009-08-27 2011-07-13 Budha Singh Dhinjan Wall bead
KR101553244B1 (ko) 2009-12-10 2015-09-15 리제너론 파마슈티칼스 인코포레이티드 중쇄 항체를 만드는 마우스
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
RU2724663C2 (ru) * 2010-02-08 2020-06-25 Ридженерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
AU2011225716A1 (en) * 2010-03-11 2012-09-27 Pfizer Inc. Antibodies with pH dependent antigen binding
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
CN103228130B (zh) 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
JP6009441B2 (ja) 2010-06-22 2016-10-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. ハイブリッド軽鎖マウス
PL2578688T5 (pl) 2011-02-25 2023-05-29 Regeneron Pharmaceuticals, Inc. Myszy adam6
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
JP6284766B2 (ja) 2011-09-30 2018-02-28 中外製薬株式会社 イオン濃度依存性結合分子ライブラリ
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
EP3165086A1 (en) 2012-03-06 2017-05-10 Regeneron Pharmaceuticals, Inc. Common light chain mouse
SG10201607727PA (en) 2012-03-16 2016-11-29 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
HUE053310T2 (hu) 2012-03-16 2021-06-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ugyanennek az elõállítására
PT2825037T (pt) 2012-03-16 2019-08-07 Regeneron Pharma Animais não humanos que expressam sequências de imunoglobulinas sensíveis ao ph
JP2015525071A (ja) 2012-06-05 2015-09-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 共通の軽鎖を用いて完全ヒト型二重特異性抗体を作製するための方法
US9962404B2 (en) 2012-09-21 2018-05-08 Reoxcyn Innovation Group, Llc Cell for electrolyzing a liquid
LT2840892T (lt) 2013-02-20 2018-07-25 Regeneron Pharmaceuticals, Inc. Nežmogaus tipo gyvūnai su modifikuotomis imunoglobulino sunkiųjų grandinių sekomis

Also Published As

Publication number Publication date
HK1200270A1 (en) 2015-08-07
IL264362B (en) 2020-05-31
MX2021000484A (es) 2022-06-08
HUE045537T2 (hu) 2019-12-30
JP2018164462A (ja) 2018-10-25
IL234237B (en) 2019-02-28
EP3539374A1 (en) 2019-09-18
MX355944B (es) 2018-05-07
JP2021007409A (ja) 2021-01-28
HRP20191333T1 (hr) 2019-10-18
KR102213535B1 (ko) 2021-02-08
WO2013138712A1 (en) 2013-09-19
KR20210018510A (ko) 2021-02-17
EP2825037A1 (en) 2015-01-21
PT2825037T (pt) 2019-08-07
NZ629077A (en) 2015-12-24
SG10202107388VA (en) 2021-08-30
SI2825037T1 (sl) 2019-08-30
RU2018128915A (ru) 2019-02-18
NZ730271A (en) 2022-09-30
JP6228589B2 (ja) 2017-11-08
KR102345232B1 (ko) 2021-12-30
KR20220002718A (ko) 2022-01-06
MX2014011048A (es) 2015-04-10
CY1121864T1 (el) 2020-07-31
CA2865645A1 (en) 2013-09-19
ES2737990T3 (es) 2020-01-17
LT2825037T (lt) 2019-08-12
IL274268B (en) 2021-12-01
RU2014141307A (ru) 2016-05-10
JP2015510769A (ja) 2015-04-13
US20170367308A1 (en) 2017-12-28
JP6574811B2 (ja) 2019-09-11
JP2017131251A (ja) 2017-08-03
US20220217955A1 (en) 2022-07-14
DK2825037T3 (da) 2019-07-29
CN107361011B (zh) 2021-08-27
US9801362B2 (en) 2017-10-31
KR102459666B1 (ko) 2022-10-27
US20140082760A1 (en) 2014-03-20
RS59076B1 (sr) 2019-09-30
KR20140135737A (ko) 2014-11-26
CN104302171B (zh) 2017-05-03
IL244098B (en) 2018-04-30
JP7011549B2 (ja) 2022-02-10
BR112014022855A2 (pt) 2017-07-18
RU2664473C2 (ru) 2018-08-17
EP2825037B1 (en) 2019-05-01
US20130247236A1 (en) 2013-09-19
PL2825037T4 (pl) 2020-03-31
NZ712508A (en) 2018-06-29
IL244098A0 (en) 2016-04-21
SG11201405171WA (en) 2014-10-30
SG10201700360VA (en) 2017-03-30
IL274268A (en) 2020-06-30
IL264362A (en) 2019-02-28
CN104302171A (zh) 2015-01-21
US9648856B2 (en) 2017-05-16
CN107361011A (zh) 2017-11-21
US11224207B2 (en) 2022-01-18

Similar Documents

Publication Publication Date Title
IL274268A (en) Non-human animals expressing immunoglobulin sequences are sensitive to PH
HK1204627A1 (en) Anti-fcrn antibodies fcrn
HK1209644A1 (en) Ctla-4 variants ctla-4
HK1204571A1 (en) Protease-regulated antibodies
HK1210192A1 (en) Anti-siglec-15 antibodies siglec-15
SG11201404663RA (en) Electroformed sheath
HK1210186A1 (en) Anti-h7cr antibodies h7cr
GB2519447B (en) Biosensors
EP2860520A4 (en) METHOD FOR DIAGNOSING MATERIAL
EP2817419A4 (en) CHIMERIC DNA IDENTIFIER
ZA201409241B (en) Fishing apparatus
GB2509299B (en) An animal trap
GB201213672D0 (en) Protein
AU4908P (en) X115-32-5 Gomphrena leontopodioides
ZA201302403B (en) Energiser
GB201205937D0 (en) Hutches
GB201218748D0 (en) Fishing aid
GB201222163D0 (en) Pet belle
GB201214501D0 (en) Protein bites
GB201215901D0 (en) Protein modification
GB201209358D0 (en) Concept ZX
GB201217861D0 (en) Fishing rods